X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SNR1611 (trametinib) was the first drug candidate identified at Genuv with the ATRIVIEW® platform. It showed the most potent neurogenerative and neuroprotective effects in a library of FDA-approved drug compounds.
Lead Product(s): Trametinib
Therapeutic Area: Neurology Product Name: SNR1611
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2022
Details:
GNUV201 is an experimental, novel anti-PD-1 monoclonal antibody developed with Genuv’s proprietary antibody development platform Shine Mouse®. GNUV201 exhibits strong cross-reactivity to both human and mouse PD-1.
Lead Product(s): GNUV201
Therapeutic Area: Oncology Product Name: GNUV201
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Nanocarry Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 06, 2022
Details:
SNR1611 is drug candidate that has been repurposed for neurodegenerative disease from a previously FDA-approved anti-cancer drug, has already confirmed SNR1611’s effect on neuron regeneration and functional recovery through preclinical research.
Lead Product(s): SNR1611
Therapeutic Area: Neurology Product Name: SNR1611
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
